Pfizer's CEO Ian Read could make almost $28 million in the next year to keep him from retiring. Strangely enough, he may earn it given the healthcare and political environment.
Worry abounds on Wall Street this week. Do you know which stocks have the lowest exposure to developments from Washington?
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Jim Cramer explains how to rely on long-term themes to take advantage of this market's wild action.